Innovex International, Inc. filings document formal disclosures for an oil and gas well-products company formed from the Dril-Quip and Innovex Downhole Solutions merger. Recent 8-K reports furnish quarterly results, earnings presentations and non-GAAP reconciliations, while proxy materials cover annual meeting matters, board governance and executive compensation.
The filing record also includes material-event disclosures on common-stock offering agreements by selling stockholders, share repurchase activity under the company's repurchase program, director changes and litigation involving Downhole Well Solutions, LLC, a wholly owned subsidiary, and friction-reduction tools used in directional drilling.
Innovex International, Inc. (INVX) is the issuer named in an amended ownership disclosure by BlackRock, Inc., which reported beneficial ownership of 7,460,672 common shares, or 10.7%, as of September 30, 2026. BlackRock reported sole voting power over 7,386,062 shares and sole dispositive power over 7,460,672 shares, with no shared voting or dispositive power. The disclosed holdings reflect certain BlackRock business units, subsidiaries and affiliates; other business units whose holdings are disaggregated are excluded.
Innovex International, Inc. (INVX) reported that Chief Executive Officer Anderson Adam had 13,463 shares of common stock withheld on September 6, 2026 to satisfy tax withholding obligations upon the release of restricted stock units. These shares were not sold in the open market. After this withholding, Adam directly holds 491,790 shares of Innovex common stock.
Innovex International, Inc. (INVX) reported that Reddout Mark, President of North America, had 5,049 shares of common stock withheld on September 6, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. After this tax-withholding disposition, he holds 119,263 shares of Innovex common stock directly, and no Rule 10b5-1 plan is reported.
Innovex International, Inc. (INVX) reported that its Chief Financial Officer, Reed Kendal, had 5,049 shares of common stock withheld on September 6, 2026 to satisfy tax withholding obligations upon the release of restricted stock units. The withholding was priced at $30.07 per share, and Kendal now directly holds 209,434 shares of Innovex common stock. No Rule 10b5-1 trading plan is reported.
Wellington Management Group LLP and related entities filed an amended Schedule 13G reporting their passive ownership in Innovex International, Inc. common stock. They report beneficial ownership of 2,687,950 shares, representing 3.91% of the outstanding common stock.
The Wellington entities report no sole voting or dispositive power, but shared voting power over 2,271,484 shares and shared dispositive power over 2,687,950 shares, held on behalf of investment advisory clients. No single client is reported to hold more than five percent of the class.
Brandes Investment Partners, L.P. filed an updated ownership report (Amendment No. 5) for Innovex International, Inc. common shares. Brandes reports beneficial ownership of 5,727,445 Innovex common shares, representing 8.330% of the outstanding class.
Brandes has shared power to vote or direct the vote for 3,606,882 shares and shared power to dispose or direct the disposition of all 5,727,445 shares. It reports no sole voting or dispositive power over Innovex shares. Brandes is organized in Delaware and signs as an investment adviser through Executive Director Glenn Carlson.
Innovex International, Inc. (INVX) had multiple affiliated investment funds report trades in its common stock. On 2026-08-10, funds associated with Amberjack Capital and Intervale Capital reported an aggregate net sale of 4,954,467 shares of common stock at $28.71 per share in an underwritten secondary offering to Barclays Capital Inc. One fund, Intervale Capital Fund III, L.P., is reported as acquiring 45,533 shares at the same price. These positions are held indirectly through various limited partnerships and general partners, which exercise voting and dispositive power over the shares. Following the transactions, Amberjack Capital Fund II, L.P. held 13,164,573 shares and Innovex Co-Invest Fund II, L.P. held 3,073,822 shares indirectly.
Innovex International, Inc. insiders affiliated with Amberjack Capital Partners and Innovex Co-Invest reported net sales of 5,000,000 shares of common stock on 2026-08-10. The shares were sold indirectly by several investment funds in an underwritten secondary offering at $28.71 per share to Barclays Capital Inc., pursuant to a Rule 10b5-1 trading plan. After these sales, Amberjack Capital Fund II, L.P. reported holding 13,164,573 shares, with other affiliated funds retaining smaller positions, and Jason Turowsky disclaimed beneficial ownership beyond his pecuniary interests.
Innovex International, Inc. is the subject of an amended Schedule 13D that updates the holdings and recent transactions of Amberjack Capital Partners and related funds. On August 6, 2026, several affiliated funds entered into an Underwriting Agreement with Barclays Capital Inc. covering the resale by these selling stockholders of 5,000,000 shares of Innovex common stock at $28.71 per share, which closed on August 10, 2026.
After this transaction, Amberjack Capital Partners and its associated vehicles may be deemed to beneficially own 17,757,322 shares of Innovex common stock, representing 25.4% of the 69,935,827 shares outstanding as of August 4, 2026. Individual funds within the structure report specific direct holdings, with Amberjack Capital Fund II holding 13,164,573 shares (18.8%) and Innovex Co-Invest Fund II holding 3,073,822 shares (4.4%). The filing also describes a Lock-up Agreement under which the selling stockholders agreed, with limited exceptions, not to transfer additional shares for 45 days after the final prospectus date without the underwriter’s consent.
Innovex International, Inc. entered into an Underwriting Agreement on August 6, 2026 with affiliates of Amberjack Capital Partners, L.P. as selling stockholders and Barclays Capital Inc. as underwriter for an underwritten secondary offering of common stock.
The selling stockholders sold 5,000,000 shares of Innovex common stock, par value $0.01 per share, to the underwriter at a price of $28.71 per sharereceived no proceeds from the sale. The secondary offering was conducted under an effective shelf registration statement on Form S-3 (File No. 333-282178), including a base prospectus dated September 17, 2024 and prospectus supplements dated August 6 and August 10, 2026. The agreement includes customary representations, warranties, conditions, termination rights and indemnification of the underwriter by the company and the selling stockholders.